Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML

Key clinical point: Azacitidine plus enasidenib improved responses in newly diagnosed AML with isocitrate dehydrogenase 2 mutations, compared with azacitidine alone. However, OS did not improve.

Major finding: Median OS was 22 months in both arms (HR 0.99, 95% CI 0.52-1.87, P = .97).

Study details: Phase 2 open label trial with 101 subjects.

Disclosures: The work was funded by enasidenib marketer Celgene. The lead investigator is an adviser to, and receives research funding from, the company.


DiNardo CD et al. EHA Congress, abstract S139.